Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA cautions against usage of Pfizer’s Chantix
The drug regulators in the US suspect Pfizer’s smoking cessation drug Chantix (varenicline), to be the cause of serious psychiatric problems. The FDA reportedly received 491 reports of
The drug regulators in the US suspect Pfizer’s smoking cessation drug Chantix (varenicline), to be the cause of serious psychiatric problems. The FDA reportedly received 491 reports of
The financial terms include an upfront cash payment to Amgen of $200 million. Takeda will also pay to Amgen up to $340 million in expected worldwide development costs
Patients being treated with BL-1020 experienced a statistically significant improvement from baseline in the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression of Severity and Improvement
The randomized, placebo-controlled, double-blind Phase II clinical trial will be conducted at 55 sites throughout the US, Europe and South America. SciClone plans to enroll a total of
The Phase I/II study evaluating indibulin combined with erlotinib is supported by preclinical studies that have demonstrated potent synergistic activity between indibulin and erlotinib. Indibulin is a novel
The US District Court of California, dismissed the case on the grounds that under state law all of the claims required showing that GSK should have included a
As part of the transaction, the Rolling Oaks Medical Group has entered into a long-term contract with RadNet, and will continue to provide all radiology services to these
Based on this approval, Genzyme will pay Isis $150 million to purchase five million shares of Isis common stock for $30 per share. Upon completion of final contracts,
Karo Bio will leverage its expertise in nuclear receptor drug discovery including structural biology, drug design and compound characterization. Zydus Cadila will carry out a focused drug discovery
The French Health Authority (Haute Autorite de Sante) granted Xience V an ASA Level IV medical benefit rating (Amelioration du Service Attendu) on recognizing the superior clinical results